janssen_latest_logo_on_sign

Janssen says its immunotherapy daratumumab extends progression-free survival in combination study to treat multiple myeloma

pharmafile | June 10, 2016 | News story | Medical Communications, Research and Development |ย ย Janssen, Phase III trials, drug trial, immunotherapy, multiple myelomaย 

Janssen said late-stage combination trials for its immunotherapy daratumumab increased progression-free survival for patients with multiple myeloma. 

The company said the Phase III study for the drug in combination with lenalidomide (an immunomodulatory agent) and dexamethasone (a corticosteroid) reduced the risk of disease progression or death by 63%.   

Professor Gordon Cook, chief investigator for the study, said: โ€œDaratumumab, the first drug of its kind, represents a significant advance in the field of multiple myeloma care. Building on successful monotherapy studies, this work shows daratumumab can be used in combination with other drugs to effectively control the disease and improve survival.” 

Advertisement

The study was conducted with 569 patients. 

Rozlyn Bekker, medical director UK and Ireland Janssen, said: โ€œWe are delighted with the results of the MMY3003 trial as itโ€™s the second Phase III study with daratumumab in combination to standard therapy to meet its primary endpoint before the final analysis.โ€ 

Daratumumab received marketing authorisation in the UK (and across the EU) in May 2016 to treat multiple myeloma. 

Anjali Shukla

Related Content

CuraCell granted approval for trial of new therapy for metastatic cancers

Swedish immunotherapy company, CuraCell, has received approval from the Paul-Ehrlich-Institut in Germany to begin a …

nerve-cell-2213009_960_720

Central nervous system cancer metastases โ€“ the evolution of diagnostics and treatment

The current forms of immunotherapy, how T cell therapy works and what the future holds

europe-1395916_640

Sanofiโ€™s Sarclisa gains EU approval for multiple myeloma treatment

Sanofi has received approval from the European Commission for the use of Sarclisa (isatuximab) in …

The Gateway to Local Adoption Series

Latest content